A phase 1/2, open-label study evaluating the efficacy, safety, and pharmacokinetics of luveltamab tazevibulin in infants and children < 12 years of age with CBFA2T3::GLIS2 acute myeloid leukemia. (ASCO 2025) - Apr 23, 2025 - Abstract #TPS10074; Pres time: May 31, 2025; 09:00 AM - 12:00 PM; Location: Hall A - Posters and Exhibits; Poster Bd #: 189a; P1/2 | "Patients without CR after 2 cycles of luvelta monotherapy may add chemotherapy (cytarabine +/- fludarabine or azacytidine) in cycle 3 and beyond...Secondary endpoints include PK levels and assessment of anti-drug antibody formation, safety, EFS and overall survival. Rates of measurable residual disease-negative CR and FRα antigen levels pre- and post-luvelta will also be explored."
Clinical • P1/2 data • PK/PD data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • CBFA2T3 • FOLR1 • GLIS2
|
|
Sarah Tasian; Himalee Sabnis; Todd Cooper; Francisco José Bautista Sirvent; Arnaud Petit; Matthew Kutny; Elizabeth Krieger; Laura Schuettpelz; AeRang Kim; Anne Borgman; Stan Frankel; Anna Butturini; Lin Lu; Kate Murray; C. Michel Zwaan
|